Drug Profile
CS 780
Latest Information Update: 12 May 2008
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Daiichi Sankyo Europe
- Class
- Mechanism of Action Nitric oxide donors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris
Most Recent Events
- 12 May 2008 Discontinued - Phase-I for Angina pectoris in USA (PO)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
- 27 Aug 2002 Discontinued - Phase-I for Angina pectoris in Japan (PO)